Francis SH - Search Results

1

Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.

Corbin JD, Zoraghi R, Francis SH. Corbin JD, et al. Among authors: francis sh. Cell Signal. 2009 Dec;21(12):1768-74. doi: 10.1016/j.cellsig.2009.07.012. Epub 2009 Aug 6. Cell Signal. 2009. PMID: 19665054 Free PMC article.

2

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.

Corbin JD, Francis SH, Webb DJ. Corbin JD, et al. Among authors: francis sh. Urology. 2002 Sep;60(2 Suppl 2):4-11. doi: 10.1016/s0090-4295(02)01686-2. Urology. 2002. PMID: 12414329 Review.

3

cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5.

Kotera J, Grimes KA, Corbin JD, Francis SH. Kotera J, et al. Among authors: francis sh. Biochem J. 2003 Jun 1;372(Pt 2):419-26. doi: 10.1042/BJ20030107. Biochem J. 2003. PMID: 12617722 Free PMC article.

4

Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.

Francis SH, Corbin JD. Francis SH, et al. Curr Urol Rep. 2003 Dec;4(6):457-65. doi: 10.1007/s11934-003-0027-x. Curr Urol Rep. 2003. PMID: 14622499 Review.

5

Allosteric sites of phosphodiesterase-5 sequester cyclic GMP.

Kotera J, Francis SH, Grimes KA, Rouse A, Blount MA, Corbin JD. Kotera J, et al. Among authors: francis sh. Front Biosci. 2004 Jan 1;9:378-86. doi: 10.2741/1231. Front Biosci. 2004. PMID: 14766375

6

Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.

Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD. Blount MA, et al. Among authors: francis sh. Mol Pharmacol. 2004 Jul;66(1):144-52. doi: 10.1124/mol.66.1.144. Mol Pharmacol. 2004. PMID: 15213306

7

Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).

Corbin JD, Beasley A, Blount MA, Francis SH. Corbin JD, et al. Among authors: francis sh. Neurochem Int. 2004 Nov;45(6):859-63. doi: 10.1016/j.neuint.2004.03.016. Neurochem Int. 2004. PMID: 15312980

8

Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil.

Zhu CB, Hewlett WA, Francis SH, Corbin JD, Blakely RD. Zhu CB, et al. Among authors: francis sh. Eur J Pharmacol. 2004 Nov 3;504(1-2):1-6. doi: 10.1016/j.ejphar.2004.09.023. Eur J Pharmacol. 2004. PMID: 15507214

9

Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation.

Zoraghi R, Bessay EP, Corbin JD, Francis SH. Zoraghi R, et al. Among authors: francis sh. J Biol Chem. 2005 Mar 25;280(12):12051-63. doi: 10.1074/jbc.M413611200. Epub 2005 Jan 27. J Biol Chem. 2005. PMID: 15677448 Free article.

10

Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.

Weeks JL, Blount MA, Beasley A, Zoraghi R, Thomas MK, Sekhar KR, Corbin JD, Francis SH. Weeks JL, et al. Among authors: francis sh. Methods Mol Biol. 2005;307:239-62. doi: 10.1385/1-59259-839-0:239. Methods Mol Biol. 2005. PMID: 15988068

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters